<DOC>
	<DOCNO>NCT02473146</DOCNO>
	<brief_summary>Purpose : The main objective study ass efficacy tolerance addition repeat dos low dos ( 3mg/m2 ) Gemtuzumab Ozogamicin ( GO ) addition standard dose Ara-C previously untreated patient age 60 80 year de novo acute myeloblastic leukemia ( AML ) non adverse cytogenetics . The main end point efficacy 2 years-event free survival . The secondary efficacy endpoint CR/Cri rate , cumulative incidence relapse overall survival . The secondary endpoint safety early death rate ( day 30 60 ) , grade 3 5 adverse event severe adverse event , cardiac toxicity quality life . Additional secondary endpoint treatment covariate interaction respect biological characteristic present diagnosis ( CD33 positivity , cytogenetic , molecular abnormality ) treatment ( Minimal residual disease level ) . This study exploratory study . Patients allocate inclusion 2/1 ratio either receive treatment GO cytarabine Idarubicin cytarabine 3+7 regimen similar `` backbone '' ALFA 1200 scheme use concurrently ALFA group treatment AML patient age &gt; 60 year . Primary objective . The primary objective ass efficacy two dos Gemtuzumab ozogamicin ( GO ) induction one dose GO first consolidation combination Cytarabine elderly patient AML non adverse cytogenetics-risk group .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin+Cytarabine v Idarubicin+Cytarabine Elderly Patients With AML.Mylofrance 4</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Patients morphologically proven diagnosis AML follow criterion : Age â‰¥ 60 year &lt; 80 year . Not previously treat disease . With favourable intermediaterisk cytogenetics . ( Patients urgent clinical need begin treatment might include cytogenetic result , necessary respond Hydroxyurea . Patients might include cytogenetic result expect time limit &lt; 5 day AML diagnosis ) . Fit receive intensive chemotherapy Cardiac function determine radionucleide echography within normal limit . Signed informed consent M3AML Presence adverse cytogenetics ( accord European LeukemiaNet recommendation . ) ( 17 ) define one follow abnormality : 5/5q , 7 , ( 6 ; 9 ) , ( v ; 11q23 ) excluding ( 9 ; 11 ) , inv ( 3 ) ( q21 ; q26.2 ) ( 3 ; 3 ) ( q21 ; q26.2 ) , complex karyotype ( 3+ abnormality ) Secondary AML follow treatment radiotherapy chemotherapy . AML follow previously know myeloproliferative myelodysplastic syndrome . ECOG performance status ( PS ) 0 3 Serum creatinin level &gt; = 2.5N ; AST ALT level &gt; = 2.5N ; total bilirubin level &gt; = 2N</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>untreated</keyword>
	<keyword>60-80 year old</keyword>
	<keyword>favorable intermediate karyotype</keyword>
</DOC>